Cell-cycle progression panel identifies prostate cancer risk

Cell-cycle progression panel identifies prostate cancer risk
The cell-cycle progression gene panel is useful to improve the risk stratification for men with even low-risk, clinically localized prostate cancer, according to research published online March 4 in the Journal of Clinical Oncology.

(HealthDay)—The cell-cycle progression (CCP) gene panel is useful to improve the risk stratification for men with even low-risk, clinically localized prostate cancer, according to research published online March 4 in the Journal of Clinical Oncology.

Matthew R. Cooperberg, M.D., M.P.H., of the University of California in San Francisco, and colleagues sought to validate a previously described genetic called CCP (that provides a value calculated from the average expression of 31 CCP genes) and its ability to improve in men with localized prostate cancer and predict recurrence after prostatectomy.

The researchers found that for each increase of one unit in the CCP score, the hazard ratio increased by 1.7, after adjusting for the patient's Cancer of the Prostate Risk Assessment Post-Surgical (CAPRA-S) score. Combining the CCP with the CAPRA-S score yielded consistently predictive outcomes across a range of clinical risk, including low-risk patients.

"The performance of the CCP score in this validation study was excellent," the authors write. "The score provided independent prognostic information after and may prove useful in helping guide decisions with respect to adjuvant treatment and in stratifying men for future adjuvant therapy studies."

Several authors disclosed financial ties to genetics firms. Myriad Genetics helped support the study.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Prostate cancer clinical stage does not predict recurrence

date Nov 22, 2010

A new study challenges the current staging system that determines the extent or severity of prostate cancer that has not metastasized. Published early online in Cancer, a peer-reviewed journal of the American Cancer Societ ...

Recommended for you

Merck drug Keytruda effective against 3 cancers

date 4 hours ago

One of the hot new cancer immunotherapy drugs, Merck & Co.'s Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to three studies presented Sunday at the American Association for Cancer ...

DNA blood test detects lung cancer mutations

date Apr 17, 2015

Cancer DNA circulating in the bloodstream of lung cancer patients can provide doctors with vital mutation information that can help optimise treatment when tumour tissue is not available, an international group of researchers ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.